{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:00:05Z","timestamp":1785243605581,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000659","name":"Research Trainees Coordinating Centre","doi-asserted-by":"publisher","award":["PCDKBRA"],"award-info":[{"award-number":["PCDKBRA"]}],"id":[{"id":"10.13039\/501100000659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00213-016-4379-6","type":"journal-article","created":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T17:26:24Z","timestamp":1470072384000},"page":"3371-3381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"233","author":[{"given":"Suzanne","family":"Reeves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"D\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Brownings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suki","family":"Greaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"4379_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10928-015-9457-6","volume":"43","author":"A Akil","year":"2016","unstructured":"Akil A et al. (2016) A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer\u2019s disease patients with agitation. J Pharmacokinet Pharmacodyn 43:99\u2013109. doi: 10.1007\/s10928-015-9457-6","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4379_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.euroneuro.2003.09.001","volume":"14","author":"N Bergemann","year":"2004","unstructured":"Bergemann N, Kopitz J, Kress KR, Frick A (2004) Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 14:245\u2013250. doi: 10.1016\/j.euroneuro.2003.09.001","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"4379_CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11920-008-0007-4","volume":"10","author":"KL Bigos","year":"2008","unstructured":"Bigos KL, Chew ML, Bies RR (2008a) Pharmacokinetics in geriatric psychiatry. Curr Psychiatry Rep 10:30\u201336","journal-title":"Curr Psychiatry Rep"},{"key":"4379_CR4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","volume":"48","author":"KL Bigos","year":"2008","unstructured":"Bigos KL et al. (2008b) Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48:157\u2013165","journal-title":"J Clin Pharmacol"},{"key":"4379_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hup.2256","volume":"27","author":"SV Bowskill","year":"2012","unstructured":"Bowskill SV, Patel MX, Handley SA, Flanagan RJ (2012) Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010. Humanist Psychol 27:507\u2013513. doi: 10.1002\/hup.2256","journal-title":"Humanist Psychol"},{"key":"4379_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/gps.4090","volume":"29","author":"C Clark-Papasavas","year":"2014","unstructured":"Clark-Papasavas C et al. (2014) Towards a therapeutic window of D2\/3 occupancy for treatment of psychosis in Alzheimer\u2019s disease, with [18F]fallypride positron emission tomography. Int J Geriatr Psychiatry 29:1001\u20131009. doi: 10.1002\/gps.4090","journal-title":"Int J Geriatr Psychiatry"},{"key":"4379_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"4379_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00023210-199606030-00006","volume":"6","author":"ALSC Coukell","year":"1996","unstructured":"Coukell ALSC, Benfield P (1996) Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6:237\u2013256","journal-title":"CNS Drugs"},{"key":"4379_CR9","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308\u20132314","journal-title":"Neurology"},{"key":"4379_CR10","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1208\/s12248-014-9649-9","volume":"16","author":"JN Dos Santos Pereira","year":"2014","unstructured":"Dos Santos Pereira JN et al. (2014) The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J 16:1247\u20131258. doi: 10.1208\/s12248-014-9649-9","journal-title":"AAPS J"},{"key":"4379_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","volume":"71","author":"SB Duffull","year":"2011","unstructured":"Duffull SB, Wright DF, Winter HR (2011) Interpreting population pharmacokinetic-pharmacodynamic analyses\u2014a clinical viewpoint. Br J Clin Pharmacol 71:807\u2013814. doi: 10.1111\/j.1365-2125.2010.03891.x","journal-title":"Br J Clin Pharmacol"},{"key":"4379_CR12","first-page":"298","volume":"3","author":"A Dufour","year":"1988","unstructured":"Dufour A, Desanti C (1988) Pharmacokinetics and metabolism of amisulpride. Ann Psychiatr 3:298\u2013305","journal-title":"Ann Psychiatr"},{"key":"4379_CR13","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1345\/aph.1E260","volume":"38","author":"EI Ette","year":"2004","unstructured":"Ette EI, Williams PJ, Lane JR (2004) Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother 38:2136\u20132144. doi: 10.1345\/aph.1E260","journal-title":"Ann Pharmacother"},{"key":"4379_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","volume":"66","author":"Y Feng","year":"2008","unstructured":"Feng Y et al. (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 66:629\u2013639. doi: 10.1111\/j.1365-2125.2008.03276.x","journal-title":"Br J Clin Pharmacol"},{"key":"4379_CR15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cmini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"4379_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jamapsychiatry.2015.0891","volume":"72","author":"A Graff-Guerrero","year":"2015","unstructured":"Graff-Guerrero A et al. (2015) Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2\/3 receptor occupancy study. JAMA Psychiatry 72:927\u2013934. doi: 10.1001\/jamapsychiatry.2015.0891","journal-title":"JAMA Psychiatry"},{"key":"4379_CR17","doi-asserted-by":"publisher","unstructured":"Haenisch B, Drescher E, Thiemer L, Xin H, Giros B, Gautron S, Bonisch H (2012) Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn Schmiedeberg's Arch Pharmacol 385:1017\u20131023. doi: 10.1007\/s00210-012-0781-8","DOI":"10.1007\/s00210-012-0781-8"},{"key":"4379_CR18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s002280050483","volume":"54","author":"B Hamon-Vilcot","year":"1998","unstructured":"Hamon-Vilcot B et al. (1998) Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. Eur J Clin Pharmacol 54:405\u2013409","journal-title":"Eur J Clin Pharmacol"},{"key":"4379_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C et al. (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195\u2013235. doi: 10.1055\/s-0031-1286287","journal-title":"Pharmacopsychiatry"},{"key":"4379_CR20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30:329\u2013332","journal-title":"Clin Pharmacokinet"},{"key":"4379_CR21","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.euroneuro.2015.08.014","volume":"25","author":"P Jennum","year":"2015","unstructured":"Jennum P, Baandrup L, Ibsen R, Kjellberg J (2015) Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 25:1906\u20131913. doi: 10.1016\/j.euroneuro.2015.08.014","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"4379_CR22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.npp.1301492","volume":"33","author":"DV Jeste","year":"2008","unstructured":"Jeste DV et al. (2008) ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33:957\u2013970","journal-title":"Neuropsychopharmacology"},{"key":"4379_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.103.053298","volume":"308","author":"JW Jonker","year":"2004","unstructured":"Jonker JW, Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2\u20139. doi: 10.1124\/jpet.103.053298","journal-title":"J Pharmacol Exp Ther"},{"key":"4379_CR24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csda.2004.07.002","volume":"49","author":"E Kuhn","year":"2005","unstructured":"Kuhn E, Lavielle M (2005) Maximum likelihood estimation in non-linear mixed effects models. Comput Stat Data Anal 49:1020\u20131038","journal-title":"Comput Stat Data Anal"},{"key":"4379_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","volume":"33","author":"IM Lako","year":"2013","unstructured":"Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K (2013) Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol 33:675\u2013681. doi: 10.1097\/JCP.0b013e3182983ffa","journal-title":"J Clin Psychopharmacol"},{"key":"4379_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11920-009-0080-3","volume":"12","author":"C Leon","year":"2010","unstructured":"Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC (2010) Sensitivity to antipsychotic drugs in older adults. Curr Psychiatry Rep 12:28\u201333. doi: 10.1007\/s11920-009-0080-3","journal-title":"Curr Psychiatry Rep"},{"key":"4379_CR27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000100779","volume":"54","author":"HK Lim","year":"2006","unstructured":"Lim HK, Pae CU, Lee C, Lee CU (2006) Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomised, open, prospective study. Neuropsychobiology 54:247\u2013251","journal-title":"Neuropsychobiology"},{"key":"4379_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/1359786806066044","volume":"20","author":"FE Lotrich","year":"2006","unstructured":"Lotrich FE, Bies RR, Smith GS, Pollock BG (2006) Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 20:33\u201340. doi: 10.1177\/1359786806066044","journal-title":"J Psychopharmacol"},{"key":"4379_CR29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6\u201314","journal-title":"Br J Clin Pharmacol"},{"key":"4379_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1600-0404.2006.00660.x","volume":"114","author":"M Mauri","year":"2006","unstructured":"Mauri M, Mancioli A, Rebecchi V, Corbetta S, Colombo C, Bono G (2006) Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer\u2019s disease. Acta Neurol Scand 114:97\u2013101. doi: 10.1111\/j.1600-0404.2006.00660.x","journal-title":"Acta Neurol Scand"},{"key":"4379_CR31","first-page":"1163","volume":"13","author":"MC Mauri","year":"2014","unstructured":"Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC (2014) Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 13:1163\u20131191","journal-title":"EXCLI J"},{"key":"4379_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","volume":"72","author":"DT Maust","year":"2015","unstructured":"Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 72:438\u2013445. doi: 10.1001\/jamapsychiatry.2014.3018","journal-title":"JAMA Psychiatry"},{"key":"4379_CR33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"IG McKeith","year":"1996","unstructured":"McKeith IG et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113\u20131124","journal-title":"Neurology"},{"key":"4379_CR34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"4379_CR35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00002512-200522050-00003","volume":"22","author":"L Merle","year":"2005","unstructured":"Merle L, Laroche ML, Dantoine T, Charmes JP (2005) Predicting and preventing adverse drug reactions in the very old. Drugs Aging 22:375\u2013392","journal-title":"Drugs Aging"},{"key":"4379_CR36","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1067\/mcp.2002.123553","volume":"71","author":"DR Mould","year":"2002","unstructured":"Mould DR et al. (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71:334\u2013348. doi: 10.1067\/mcp.2002.123553","journal-title":"Clin Pharmacol Ther"},{"key":"4379_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/0269881108089806","volume":"23","author":"MJ Muller","year":"2009","unstructured":"Muller MJ, Eich FX, Regenbogen B, Sachse J, Hartter S, Hiemke C (2009) Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol 23:278\u2013286. doi: 10.1177\/0269881108089806","journal-title":"J Psychopharmacol"},{"key":"4379_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jpsychires.2005.10.003","volume":"41","author":"MJ Muller","year":"2007","unstructured":"Muller MJ, Regenbogen B, Hartter S, Eich FX, Hiemke C (2007) Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 41:673\u2013679. doi: 10.1016\/j.jpsychires.2005.10.003","journal-title":"J Psychiatr Res"},{"key":"4379_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-2006-931540","volume":"39","author":"MJ Muller","year":"2006","unstructured":"Muller MJ, Regenbogen B, Sachse J, Eich FX, Hartter S, Hiemke C (2006) Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry 39:41\u201346. doi: 10.1055\/s-2006-931540","journal-title":"Pharmacopsychiatry"},{"key":"4379_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.320","volume":"17","author":"P Rosenzweig","year":"2002","unstructured":"Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Humanist Psychol 17:1\u201313. doi: 10.1002\/hup.320","journal-title":"Humanist Psychol"},{"key":"4379_CR41","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","volume":"51","author":"A Samson","year":"2006","unstructured":"Samson A, Lavielle M (2006) Extension of the SAEM algorithm to left-censored data in nonlinear nixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 51:1562\u20131574","journal-title":"Comput Stat Data Anal"},{"key":"4379_CR42","doi-asserted-by":"publisher","unstructured":"Seeman P (2014) Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 29:1096 doi: 10.1002\/gps.4133","DOI":"10.1002\/gps.4133"},{"key":"4379_CR43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11\u201319","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"4379_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","volume":"120","author":"A Sparshatt","year":"2009","unstructured":"Sparshatt A, Taylor D, Patel MX, Kapur S (2009) Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 120:416\u2013428. doi: 10.1111\/j.1600-0447.2009.01429.x","journal-title":"Acta Psychiatr Scand"},{"key":"4379_CR45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JGP.0b013e318198776d","volume":"17","author":"H Uchida","year":"2009","unstructured":"Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC (2009a) Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 17:255\u2013263","journal-title":"Am J Geriatr Psychiatry"},{"key":"4379_CR46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.08r04171","volume":"70","author":"H Uchida","year":"2009","unstructured":"Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S (2009b) Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 70:397\u2013405","journal-title":"J Clin Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-016-4379-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4379-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:41:54Z","timestamp":1498318914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-016-4379-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":46,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["4379"],"URL":"https:\/\/doi.org\/10.1007\/s00213-016-4379-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}